Answers are grounded in this paper and cite their sources.
Metastatic colorectal cancer (mCRC) is characterized by molecular heterogeneity and the development of adaptive resistance to systemic therapies. Biomarkers have become central to understanding resistance biology and guiding treatment selection, spanning established genomic alterations, circulating tumor DNA (ctDNA)-based monitoring, and emerging molecular classifications. Herein, we provide a synthesis of biomarker-driven resistance mechanisms across major therapeutic classes in mCRC, including anti-EGFR, anti-VEGF, BRAF-targeted, KRAS-targeted, HER2-directed, and immunotherapy-based approaches. PubMed/MEDLINE and Google Scholar were searched for relevant literature published through August 2026. Resistance to targeted therapies converges on reactivation of key signaling pathways, particularly MAPK, through genomic and microenvironmental factors. ctDNA represents an important tool for longitudinal assessment of tumor evolution and has demonstrated clinical validity in selected settings, including molecular selection for anti-EGFR rechallenge. Across other therapeutic classes, ctDNA dynamics and resistance profiling are primarily prognostic or investigational, and prospective evidence that ctDNA-guided treatment adaptation improves outcomes remains limited. Emerging biomarkers, including immune-related gene expression patterns, features of the tumor microenvironment, and metabolic adaptations, may improve prediction of therapeutic response. Integration of longitudinal biomarker assessment with ctDNA profiling may enable earlier detection of resistance and more individualized treatment strategies, although the clinical benefit of ctDNA-guided treatment adaptation remains to be established.
No takes yet. Share an insight, caveat, or question.
Eslinger et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: